CUV 0.00% $14.30 clinuvel pharmaceuticals limited

Ann: FDA Type C Meeting for SCENESSE in Vitiligo, page-2

  1. 970 Posts.
    lightbulb Created with Sketch. 529
    unmet needs
    goals to be the first company to launch product addressing vitiligo patients

    https://hotcopper.com.au/data/attachments/2129/2129503-ece7f7d26a3fc6d0ae2e72d1e947dc47.jpg

 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.